Automated, large-scale and GMP-compliant cell manufacturing
Learn how to implement manufacturing of different adherent cell types in the fully closed and automated CliniMACS Prodigy® Adherent Cell Culture System
Thursday 21 February 2019
07:00 [PST] 10:00 [EST] 15:00 [GMT]
Regenerative medicine has become a key focus worldwide and the number of stem cell therapy trials are rapidly increasing every year. Yet, large-scale and GMP-compliant stem cell manufacturing is still a major hurdle for clinical applications across the globe. In this webinar, we will show you how to implement GMP-compliant and scalable manufacturing of different adherent cell types, such as pluripotent stem cells and their derivatives, in the CliniMACS Prodigy® Adherent Cell Culture System.
What will you learn?
- How to build customized protocols using the modularized system
- How to connect external culture vessels for large-scale cultivation
- How to manufacture pluripotent stem cells, dopaminergic progenitors, and mesenchymal stem cells in a closed and automated system
- Benefits of using CliniMACS Prodigy® Adherent Cell Culture System for cell manufacturing
Who may this interest?
- Cell therapy providers and CMOs
- Researchers and companies in translational research
- GMP facilities
- Professionals in cell manufacturing and process development
Dr. Chao Sheng
Product Manager - Regenerative Medicine
Miltenyi Biotec GmbH
Chao is the Product Manager for Regenerative Medicine products at Miltenyi Biotec. He has extensive experiences with expansion and directed differentiation of pluripotent stem cells, neuroscience, cell culture reagents, and automated cell manufacturing. Chao performed his PhD and Postdoc studies in the Chinese Academy of Sciences and the University of Bonn focusing on cell fate (re)programming. He joined Miltenyi Biotec's marketing team in 2018.
Dr. Sebastian Knöbel
Manager Research & Development
Miltenyi Biotec GmbH
Sebastian Knöbel is Manager in the R&D heading the media development group and research groups for pluripotent and mesenchymal stem cells generating tools and protocols for the isolation, culture and modulation of cells for research and translational applications. The current research includes many aspects of regenerative cell therapy with a focus on application development for automated manufacturing of stem cell derived cell products.
In association with